

An Excellent Example of an Early Arthritis Clinic — What Is Its Clinical Value?



EARLY ARTHRITIS IN POPULATION STUDIES

Research concerning early arthritis and early rheumatoid arthritis (RA) may be thought to have begun in population-based studies in the late 1950s to late 1960s. These studies indicated that the majority of people who had clinical findings of RA had no evidence of disease 3–5 years later¹, and that only about 25%–30% of people in a population who met criteria for RA had rheumatoid factor. These observations were thought for many years to apply to RA as seen in rheumatology clinical settings. However, they appear to apply to a different population, as many of those identified in these epidemiologic studies likely never saw a physician, and their symptoms resolved spontaneously. Therefore, instead of improving understanding of clinical RA, these early findings may have contributed to an underestimation of clinical RA until the severity of longterm outcomes of patients who were seen in rheumatology settings were recognized in the 1980s and later^{2–4}, on the basis of longitudinal followup of clinical cohorts for 10–40 years.

THE MOVEMENT TOWARD EARLY ARTHRITIS CLINICS

Emery and Gough⁵ pointed out that RA is the most common cause of potentially treatable disability in Western countries, based on recognition of longterm severity of clinical RA^{2–4}. At that time, general practitioners were advised to give patients a nonsteroidal antiinflammatory drug for up to 2 years before the use of disease modifying antirheumatic drugs (DMARD)⁶. During that interval, the optimal window of opportunity to treat RA inflammation might be lost in many patients. A need for early arthritis clinics was advocated, with desirable characteristics of a large referral population, knowledgeable and cooperative primary care physicians, and an enthusiastic organizer⁵.

EARLY TREATMENT IS BENEFICIAL IN RANDOMIZED CLINICAL TRIALS

Observations from randomized clinical trials (RCT) support early versus delayed drug treatment in RA. The benefits of early versus delayed treatment have been documented in studies of intramuscular gold, auranofin, sulfasalazine, and hydroxychloroquine (as reviewed⁷). One metaanalysis indicated that disease duration at the time of DMARD initiation was the primary predictor of the response to DMARD treat-

ment⁸. In the FIN-RACo trial, delay of 4 months of the initiation of a DMARD diminished the likelihood of remission⁹. One study concluded that very early treatment with methotrexate may postpone the development of RA¹⁰.

IMPROVED LONGTERM OUTCOMES OF RA REFLECT EARLY AND ACTIVE TREATMENT STRATEGIES

Data from clinical cohorts and observational studies indicate that status and outcomes of RA patients have improved over the past decades concomitantly with implementation of early and active treatment strategies^{11,12}. Improvements have been seen in disease activity, functional capacity, radiographic scores, and other clinical measures including lower mortality rates in patients who responded to methotrexate and to biological therapies, lower rates of joint replacement surgery at this time compared to earlier decades, and lower work disability rates in patients who responded to DMARD (as reviewed¹³). On the other hand, high levels of disease activity are still seen in many clinics in many countries and in some patients in all countries¹⁴.

CLINICAL VALUE OF “VERY EARLY ARTHRITIS” CLINICS?

Recognition of severe longterm outcomes of RA in the early 1980s led to the call for aggressive strategies to treat RA, including early intervention. Benefits of early and active treatment strategies have been shown in randomized controlled trials and observational studies such as described above. Is further improvement needed in terms of early interventions?

In the current issue of *The Journal*, Mjaavatten, *et al*¹⁵ provide an example of a well-functioning early arthritis clinic, with description of the pattern of joint involvement and its influence on patients' health status. Establishment of an early arthritis clinic is admirable. However, only a few centers have been able to establish such clinics, most often as part of early arthritis research projects.

Early arthritis clinics are in fashion at this time. However, their cost/benefit value may be questioned for at least 3 reasons:

1. An early arthritis clinic should possibly be established to identify patients who would develop destructive arthritis, such as stated by Mjaavatten, *et al*¹⁵. Recognition of RA in the early stages is both important and difficult. Criteria for

See Pattern of joint involvement in early arthritis, page 1401

RA have been developed since 1907¹⁶. However, the current set of criteria for RA, the American Rheumatism Association (now the American College of Rheumatology) ACR 1987 revised criteria, do not differentiate individual patients with early RA from those with other types of recent-onset inflammatory polyarthritides.

2. Early arthritis clinics might conduct research to identify biomarkers for patients who would develop destructive arthritis. However, none of the current biomarkers identifies more than two-thirds of patients who will develop destructive arthritis, and even in the present study, one of the available prediction models failed. About 40% of patients with RA have a normal erythrocyte sedimentation rate or C-reactive protein at first visit¹⁷. A recent metaanalysis indicated that rheumatoid factor is positive in 69%, and antibodies to cyclic citrullinated proteins (anti-CCP) in 67% of patients with RA¹⁸. To date, early arthritis clinics have not led to new markers for longterm destructive disease.

3. A third rationale for early arthritis clinics might be to postpone development of RA with methotrexate¹⁰ or other early treatment. In the Oslo early arthritis clinic, however, only 28% of patients received a DMARD over the first year¹⁵.

QUANTITATIVE LONGITUDINAL DATA COLLECTION IN ROUTINE RHEUMATOLOGY CARE

There certainly appears to be a need for a few early arthritis clinics as research projects, to discover and apply new information to this important problem. At this time, however, the primary lessons may be that there are no more advanced markers to recognize progressive disease, other than longitudinal observation of the patient. In most treatment settings, the early arthritis clinic may consume financial and human resources from this important need for all rheumatology treatment sites. Even observations from well established early arthritis clinics without longterm followup of patients remain a temporary exercise without the capacity to improve clinical care.

Mjaavatten, *et al*¹⁵ have established a very early arthritis cohort. Longitudinal followup of this cohort and other such cohorts over years and decades will bring light to the course of very early arthritis. Whether that light is still needed, in the era of active strategies to treat clinical patients with RA using available drugs and tight control according to quantitative monitoring, remains to be seen.

TUULIKKI SOKKA, MD, PhD,
Jyväskylä Central Hospital, Jyväskylä,
and Rheumatism Foundation Hospital,
Heinola;

HEIDI MÄKINEN, MD, PhD,
Jyväskylä Central Hospital, Jyväskylä,
and Tampere University Hospital,
Tampere, Finland

Address correspondence to Dr. T. Sokka, Arkisto/Tutkijat, Jyväskylä Central Hospital, 40620 Jyväskylä, Finland.
E-mail: tuulikki.sokka@kssh.fi; tuulikki_sokka@hotmail.com

REFERENCES

1. Sokka T, Pincus T. A historical perspective concerning population-based and clinical studies of early arthritis and early rheumatoid arthritis. *Clin Exp Rheumatol* 2003;21:S5-S14.
2. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. *Arthritis Rheum* 1984;27:864-72.
3. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA. Progression of radiological changes in rheumatoid arthritis. *Ann Rheum Dis* 1984;43:8-17.
4. Rasker JJ, Cosh JA. The natural history of rheumatoid arthritis: a fifteen year follow-up study. The prognostic significance of features noted in the first year. *Clin Rheumatol* 1984;3:11-20.
5. Emery P, Gough A. Why early arthritis clinics? *Br J Rheumatol* 1991;30:241-2.
6. Lightfoot RW Jr. Treatment of rheumatoid arthritis. In: McCarty DJ, editor. *Arthritis and allied conditions*. 10th ed. Philadelphia: Lea & Febiger; 1985:668-76.
7. Sokka T, Makinen H. Drug management of early rheumatoid arthritis — 2008. *Best Pract Res Clin Rheumatol* 2009;23:93-102.
8. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. *Arthritis Rheum* 2000;43:22-9.
9. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. *Lancet* 1999;353:1568-73.
10. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. *Arthritis Rheum* 2007;56:1424-32.
11. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. *Arthritis Rheum* 2005;52:1009-19.
12. Sokka T, Kautiainen H, Mottonen T, Hannonen P. Erosions develop rarely in joints without clinically detectable inflammation in patients with early rheumatoid arthritis. *J Rheumatol* 2003;30:2580-4.
13. Sokka T. Quantitative assessment of rheumatoid arthritis in standard clinical care: turning clinical care into clinical science. *Best Pract Res Clin Rheumatol* 2007;21:653-61.
14. Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. *Ann Rheum Dis* 2007;66:1491-6.
15. Mjaavatten MD, Haugen AJ, Helgetveit K, et al. Pattern of joint involvement and other disease characteristics in 634 patients with arthritis of less than 16 weeks' duration. *J Rheumatol* 2009;36:1401-6.
16. Allbutt T, Rolleston H. *A system of medicine*. London: Macmillan; 1907.
17. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from Finland and the United States. *J Rheumatol* 2009; Epub May 1.
18. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. *Ann Intern Med* 2007;146:797-808.

J Rheumatol 2009;36:1355–6; doi:10.3899/jrheum.090441